Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 12:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 429 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "biochemical recurrence" Clear all
Completed Phase 3 Interventional Results available

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

NCT03274687
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions
Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Radiation Therapy
Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
229
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 188 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 12:41 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Vitamin B6 Effects for Women Taking Birth Control Pills

NCT01128244
View directory record Official record
Conditions
Vitamin B6 Deficiency
Interventions
Vitamin B6, Infusion of labeled serine, methionine and leucine
Dietary Supplement · Procedure
Lead sponsor
University of Florida
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Jul 23, 2026, 12:41 PM EDT
Withdrawn Phase 2 Interventional

Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer

NCT00694291
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sorafenib, Placebo
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Jul 23, 2026, 12:41 PM EDT
Withdrawn No phase listed Observational

Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer

NCT04243473
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jul 23, 2026, 12:41 PM EDT
Recruiting Phase 3 Interventional

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

NCT04423211
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy
Radiation · Drug · Procedure + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
342
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 23, 2026, 12:41 PM EDT
Completed Phase 1 Interventional

Biological Therapy in Treating Patients With Metastatic Cancer

NCT00004604
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions
CEA RNA-pulsed DC cancer vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Jul 23, 2026, 12:41 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer

NCT05779943
View directory record Official record
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions
Furosemide, F18-rhPSMA-7.3, Positron Emission Tomography, Computed Tomography
Drug · Other · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Jul 23, 2026, 12:41 PM EDT
Completed Phase 2 Interventional Results available

A Study of Patients Receiving High-Dose Rate Brachytherapy

NCT00924027
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Prostate Cancer, Biliary Cancer
Interventions
High Dose Radiation (HDR) Brachytherapy, MRI, CT, PET Scan
Radiation · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jul 23, 2026, 12:41 PM EDT
Terminated Phase 2 Interventional

Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00176527
View directory record Official record
Conditions
Prostate Cancer
Interventions
recombinant interferon alfa-2b, docetaxel, estramustine phosphate sodium, isotretinoin, polyacrylamide gel electrophoresis, protein expression analysis, immunohistochemistry staining method
Biological · Drug · Genetic + 1 more
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Jul 23, 2026, 12:41 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer

NCT01603420
View directory record Official record
Conditions
Prostate Cancer
Interventions
Luteinizing hormone-releasing hormone (LHRH), Docetaxel, Conformal Radiation Therapy (RT)
Drug · Other
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years to 75 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Warrenville, Illinois • Oklahoma City, Oklahoma • Hampton, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Jul 23, 2026, 12:41 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

NCT01531205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Jul 23, 2026, 12:41 PM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

NCT04931342
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Ipatasertib, Cobimetinib, Trastuzumab Emtansine, Atezolizumab, Bevacizumab, Paclitaxel, Giredestrant, Abemaciclib, Inavolisib, Palbociclib, Letrozole, Olaparib, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, Cyclophosphamide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
8
States / cities
San Francisco, California • St Louis, Missouri • Charlotte, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 23, 2026, 12:41 PM EDT
Recruiting Not applicable Interventional

Technology Assisted Motivational Interviewing

NCT06713603
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
TAMI Coach
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Jul 23, 2026, 12:41 PM EDT
Completed No phase listed Observational

Prostate Biomarker Study

NCT00574899
View directory record Official record
Conditions
Prostate Cancer
Interventions
Questioners, blood specimens, prostate tissue specimens
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
35 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Jul 23, 2026, 12:41 PM EDT
Completed Phase 1 Interventional

Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

NCT01548807
View directory record Official record
Conditions
Prostate Cancer Patients With Detectable PSA Following Prostatectomy
Interventions
Everolimus (RAD001)
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Jul 23, 2026, 12:41 PM EDT
Terminated Phase 2 Interventional

A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer

NCT00672009
View directory record Official record
Conditions
Prostatic Diseases, Genital Neoplasms, Male, Urogenital Neoplasms, Genital Diseases, Male, Adenocarcinoma, Prostatic Neoplasms, Neoplasms, Glandular and Epithelial, Carcinoma
Interventions
Ixabepilone
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Jul 23, 2026, 12:41 PM EDT
Terminated Phase 3 Interventional Results available

External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer

NCT00388804
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy, Bicalutamide, Leuprolide, Goserelin, Flutamide, Questionnaire
Procedure · Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Jul 23, 2026, 12:41 PM EDT
Completed Phase 2 Interventional Results available

Combination Immunotherapy in Biochemically Recurrent Prostate Cancer

NCT03315871
View directory record Official record
Conditions
Prostate Cancer
Interventions
Antigen direct immunotherapy: PROSTVAC-V, Antigen direct immunotherapy: PROSTVAC-F, MSB0011359C (M7824), Antigen direct immunotherapy: CV301, CT scan of chest, CT scan of abdomen/pelvis, MRI, PSMA, Bone scan
Biological · Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Jul 23, 2026, 12:41 PM EDT
Completed Phase 1 Interventional

Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer

NCT02184533
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer, Multiple Myeloma, Plasmacytoma
Interventions
sodium selenite, radiation therapy, laboratory biomarker analysis, pharmacological study, questionnaire administration
Drug · Radiation · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 27, 2024 · Synced Jul 23, 2026, 12:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

QST Study: Predicting Treatment Response in Chronic Pancreatitis Using Quantitative Sensory Testing

NCT03434392
View directory record Official record
Conditions
Chronic Pancreatitis, Chronic Pain
Interventions
Quantitative Sensory Test 1, Quantitative Sensory Test 2, Quantitative Sensory Test 3
Diagnostic Test
Lead sponsor
Anna Evans Phillips
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jul 23, 2026, 12:41 PM EDT
Active, not recruiting Phase 2 Interventional

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

NCT03181867
View directory record Official record
Conditions
Prostate Neoplasms, Prostatic Cancer, Prostate Cancer, Cancer Of Prostate, Metastatic Prostate Cancer
Interventions
18F-DCFPyL, 18F-FDG, PSMA-11
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 12:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

NCT00879619
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
sunitinib malate, docetaxel, prednisone
Drug
Lead sponsor
John P. Fruehauf
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jul 23, 2026, 12:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer

NCT06574880
View directory record Official record
Conditions
Malignant Neoplasm of Prostate, Locally Advanced Prostate Cancer
Interventions
Lu-PSMA-617, 5-fraction Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Angela Y. Jia, MD PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 23, 2026, 12:41 PM EDT
Active, not recruiting Phase 2 Interventional

Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C)

NCT03525262
View directory record Official record
Conditions
Prostate Cancer Adenocarcinoma
Interventions
30Gy (Gray) planning target volume (PTV)
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Colorado Springs, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 23, 2026, 12:41 PM EDT